Articles tagged with Breast Cancer
Researchers at UNC Lineberger Comprehensive Cancer Center will study the impact of financial navigation services on rural cancer patients in North Carolina. The study aims to connect patients with potential financial support resources and reduce financial toxicity associated with cancer care.
The ONCOMMUN Program aims to improve patient experience and reduce the impact of cancer in Europe. The program combines monitoring of health and emotional status with video-consultations, online education, and social networking to increase quality of life and therapeutic adherence.
The UW's Optimizing Implementation in Cancer Control Center will develop knowledge and tools to support optimal implementation of proven cancer interventions. The center will focus on optimizing screening evidence-based interventions for cervical, colorectal, breast, and ovarian cancers.
A non-invasive imaging technique can assess tumor stiffness, providing valuable diagnostic information about breast and pancreatic tumors. The technique, magnetic resonance elastography, may help select the best treatment course for some cancer patients.
A Colorado study found that lymphoma stage at diagnosis impacts types of second cancers that may form after treatment. Early-stage patients had a higher risk of solid tumors, while late-stage patients were more likely to develop hematologic malignancies.
Researchers used state-of-the-art technology to profile each cell during normal breast development, creating a molecular map to understand how breast tissues are formed and maintained. The team found that cells were already poised to become either basal or luminal cells before birth, with abnormal alterations leading to tumor development.
A new analysis published in Annals of Oncology suggests that hormone therapy has a greater impact on women's quality of life compared to chemotherapy, especially in postmenopausal patients. This finding challenges current international guidelines recommending prolonged hormone therapy for 5-10 years.
Breast cancer researchers at the University of Notre Dame have identified a pair of proteins, CXCL5 and CXCR2, critical for spreading breast cancer to bone. These proteins cause cancer cells to rapidly reproduce and spread throughout the bone and marrow.
A recent analysis reveals that treatment of male breast cancer has evolved over the years, with certain patient- and tumor-related factors linked to better survival. The study found that older age, black race, multiple comorbidities, high tumor grade, and undergoing total mastectomy were associated with worse overall survival.
A new type of drug that blocks one of cancer's key evolutionary escape routes from chemotherapy has been shown to reinvigorate the response to chemotherapy in cancers that had become resistant. The drug, BOS172722, works by forcing cancer cells through cell division too quickly, leading to fatal errors.
A recent study found that aggressive breast cancers store large amounts of glycogen, a stored collection of glucose molecules. This stored energy enables the cancer cells to grow and spread. Researchers believe that targeting the enzyme PYG could be a potential target to treat or prevent breast cancer metastasis.
Researchers have identified FGFR3 mutations in a subset of meningioma patients with favorable prognoses, suggesting potential for targeted therapy. These mutations may enhance diagnostic accuracy and clinical decision-making.
Researchers found that multigene testing for all patients with breast cancer can be a cost-effective approach, reducing healthcare costs and improving patient outcomes. The study compared the cost-effectiveness of multigene testing to selective testing based on family history or clinical criteria.
The breast cancer death rate has slowed in recent years, but the gap between black and white women remains significant. Breast cancer incidence rates have continued to rise, with a greater increase seen in hormone receptor-positive disease.
Researchers at Arizona State University have discovered a common source of tumor mutations that could lead to the development of universal cancer vaccines. They found that errors in RNA transcription and splicing in tumors can produce unique protein fragments, or peptides, that can be recognized by the immune system.
A University of South Florida researcher is studying whether a home-based exercise program can decrease the severity of nerve and muscle symptoms from chemotherapy-induced peripheral neuropathy in breast cancer survivors. The study aims to provide an evidence-based intervention for patients suffering from persistent neuropathy.
Researchers at UC Riverside are developing a novel small molecule that selectively targets the PCNA protein in breast cancer cells. The project aims to create a new series of AOH1160-like molecules to improve the clinical management of breast cancer patients, while sparing non-cancerous cells.
Researchers will examine microRNAs and enhancer RNA to understand treatment resistance and metastasis of ER-positive breast cancer. The goal is to develop a new treatment strategy for patients with limited options.
A study published in Nature Medicine suggests that whole genome sequencing of tumour cells can predict prognosis and identify effective treatments for patients with triple negative breast cancers. The technique reveals genetic signatures and mutations, providing clues to develop new drugs and improve treatment outcomes.
The TAILORx trial has shown that women with high Recurrence Scores (26-100) have a 93% chance of being cancer-free after five years, with those receiving chemotherapy having a significantly better outcome. The findings support the use of adjuvant chemotherapy to improve treatment outcomes in early breast cancer patients.
A new phase III trial found that immune therapy added to chemotherapy improved pathological complete response in patients with early triple negative breast cancer, leading to a clinically meaningful benefit and potential cure for more patients. The study also indicated an improvement in event-free survival.
Two studies show that CDK4/6 inhibitors plus fulvestrant significantly improve overall survival in hormone receptor-positive advanced breast cancer. The combination is recommended as a standard of care for patients with metastatic disease.
A study by UCLA researchers found that adding ribociclib to standard hormone therapy significantly improves overall survival in postmenopausal women with advanced hormone-receptor positive/HER2- breast cancer. The combination treatment demonstrated a 28% reduction in risk of death and improved progression-free survival.
A study published in the American Journal of Roentgenology found that ultrasound screening after digital mammography and digital breast tomosynthesis yielded no significant difference in additional cancer detection rate. The findings suggest that DBT does not obviate additional US screening for women with dense breast tissue.
A new trial analysis found that women diagnosed with early stages of cancer who undergo lumpectomies and receive either partial or whole breast radiation have equivalent cosmetic outcomes, according to patient and physician ratings. The study's findings aim to guide women seeking breast-conserving therapy for early-stage disease.
Researchers used a new technique to identify genetic profiles of individual cells in a breast cancer tumor and found a drug combination that reversed resistance. The study suggests that clinicians could begin combination therapy before resistance occurs, given the effectiveness of the additional drug.
ECOG-ACRIN announces late-breaking TAILORx data on chemotherapy regimens for early-stage breast cancer. The data, published concurrently in JAMA Oncology, focuses on patients with a score of 26-100 on the 21-tumor gene recurrence score assay.
A study by The World Cancer Research Fund and the American Institute for Cancer Research suggests that lifestyle modifications can prevent up to 30% of breast cancer cases. The recommended modifications include maintaining a healthy weight, engaging in regular physical activity, and consuming a balanced diet rich in non-starch vegetables.
A UMass Amherst research team will investigate the effect of a fruit and vegetable-rich diet on breast cancer risk in lactating women. The New Moms Wellness Study, funded by a $3.1 million NIH grant, aims to assess biomarkers of breast cancer risk using breastmilk.
A study published in Nutrition and Cancer found that consuming sofrito, which includes onions and garlic, was associated with a reduced risk of breast cancer. Women who ate sofrito more than once per day had a 67% decrease in risk compared to those who never ate it.
Researchers developed new prediction models to improve personalized treatment of lymph nodes in breast cancer patients. The models show that up to one in three operations could be avoided, reducing surgical interventions by 30%.
A study of nearly 1.9 million breast cancer patients found that men have lower three-year and five-year survival rates compared to women. The analysis attributed the difference to undertreatment and clinical characteristics.
Researchers at LSU Health found that metformin can delay mammary gland development, enhance tumor growth and metastasis, and decrease AMPK activation. The study suggests metformin's therapeutic value in treating breast cancer in patients with low Nischarin expression levels.
A landmark study found that selective mammography screening can detect male breast cancer in high-risk men at an early stage, improving survival prognosis. The cancers detected were often benign, but the study's results support targeted screening for men with elevated risk.
Researchers discovered that some cancer cells survive chemotherapy by consuming neighboring tumor cells, providing energy to stay alive. This process helps senescent cancer cells initiate tumor relapse after treatment completion.
A recent study found that men at high risk for breast cancer can benefit from mammography screening. The study involved 1,869 men who had a mammogram between 2005 and 2017, with 41 men diagnosed with breast cancer.
A substudy of the NRG Oncology clinical trial found that women rated post-lumpectomy partial breast irradiation as equivalent to whole breast irradiation in terms of cosmetic outcomes and satisfaction. The results suggest that PBI may be a viable option for patients seeking to minimize radiation time commitment and healthcare costs.
A $3 million Stand Up 2 Cancer grant supports a clinical trial evaluating a combination therapy to prevent triple-negative breast cancer recurrence. The trial will utilize a blood test to identify women at risk and harness the immune system to eliminate the cancer.
Research found that only 35% of eligible women took part in all three screening programmes, with 10% remaining unscreened. Women from areas of less deprivation and those with caring duties were more likely to take up screenings, while practices with higher proportions of unemployed patients and smokers had lower rates.
Scientists have identified distinctive characteristics of KRAS-positive lung cancers that can be targeted to inhibit growth, offering a new approach for personalized therapy. The study suggests exploring co-existing mutations as an alternative to traditional therapies.
Research reveals how breast cancer cells use exosomes to bypass the blood-brain barrier and spread to the brain. Exosomes trick endothelial cells into taking them up, allowing cancer cells to metastasize, and can also manipulate astrocytes to facilitate tumor growth.
Researchers discovered that E-cadherin promotes metastasis in invasive ductal carcinoma by allowing breast cancer cells to survive during travel and form new tumors. The study reveals that the process of metastasis is inefficient, with only 1% of cells surviving and forming new tumors.
A new clinical trial, EAZ171, is recruiting black women with breast cancer to investigate and treat taxane-induced neuropathy. The study seeks to identify the most effective chemotherapy regimen for African American women, who are disproportionately affected by this debilitating side effect.
A study supports genetic testing for all metastatic breast cancer patients to identify additional patients with increased risk of certain mutations. This strategy may also help determine response to targeted therapies such as PARP inhibitors for HER2/ERBB2 negative breast cancer.
A new study suggests that older women with chronic illnesses, such as cardiovascular disease or diabetes, may not derive significant benefits from regular screening mammograms. The research found a nearly 90-fold difference in mortality rates between breast cancer and non-breast cancer causes among women aged 75 and older.
Researchers tested immunotherapy in young and old mice with triple negative breast cancer, finding that age affects the efficacy of ICB therapy. The study found significant reduction in tumor growth and better overall survival rates in young mice compared to aged mice.
A large cohort study found that obesity is consistently associated with a greater burden of symptoms and experiences of distress among patients with breast or prostate cancer. Among patients with colon cancer, significant symptoms and distress were observed regardless of weight, suggesting alternative factors at play.
A new study published in the Journal of Nutrition found that a low-fat diet rich in fruits, vegetables, and grains reduces death following breast cancer, slows diabetes progression, and prevents coronary heart disease. The study, led by Fred Hutchinson Cancer Center researchers, followed nearly 49,000 postmenopausal women for nearly 20...
A non-coding region of the genome has been discovered to regulate the development of cancer in various types of tumors, including breast cancer and sarcomas. The RPSAP52 RNA molecule triggers cell proliferation and cancels differentiation, allowing tumor cells to multiply and spread.
The USPSTF recommends medications like tamoxifen, raloxifene, or aromatase inhibitors to reduce breast cancer risk in asymptomatic women over 35 with increased risk but low adverse effects risk. The Task Force advises against routine use for women not at high breast cancer risk.
Researchers from Osaka University have identified a gene, GREB1, as a key player in the development of hepatoblastoma. The study found that suppressing GREB1 production using antisense oligonucleotides significantly reduced tumor formation and cell proliferation in mouse liver cancer models.
A new study analyzing worldwide epidemiological evidence finds a significant association between menopausal hormone therapy and breast cancer incidence. The research indicates that the risks are greater for users of oestrogen-progestagen hormone therapy than for oestrogen-only hormone therapy.
A new study identifies PoEMs as promoting breast cancer metastasis through the loosening of lymph vessel connections. Removing these cells reduces the ability of breast cancer cells to spread. The findings suggest targeting PoEMs in cancer therapy, specifically targeting cancer-associated lymphatic vessels.
Researchers at UT Health San Antonio have identified a novel way to kill cancers caused by inherited BRCA1 mutations. Adding back microRNA 223-3p forces BRCA1-mutant cancer cells to die, offering a potential treatment for inherited breast and ovarian cancer.
Researchers found large diversity in neutrophil and macrophage frequencies, with some tumors attracting one type while others attract the other. The study highlights heterogeneity of tumor cells and immune microenvironment as important considerations for therapy.
Women with breast cancer who experience depression, anxiety, or mental health conditions are more likely to use opioids and have lower survival rates. Researchers recommend alternative pain management options like physical therapy, massage, and acupuncture to improve treatment outcomes.
Oncologists suggest using nab-paclitaxel instead of paclitaxel prior to surgery for high-risk breast cancer patients, potentially improving long-term outcomes and reducing disease recurrence. This approach may be particularly beneficial for women with hormone receptor positive, HER-2 negative breast cancer.
A new CRISPR gene editing system, encapsulated in a nanolipogel, effectively targets and knocks out the Lcn2 oncogene, curbing tumor growth in mice, providing a potential genetic treatment for triple-negative breast cancer.
Researchers compared three frontline breast cancer drugs and found significant differences in their biological activity. Abemaciclib was shown to be more effective than other drugs at high doses, affecting proteins beyond CDK4/6, suggesting it may work differently for patients who don't respond to other treatments.
Researchers at Moffitt Cancer Center have developed a model called GARD that uses genomic data to predict the risk of local tumor recurrence and optimize radiation doses for breast cancer patients. The study found that a personalized approach to radiation therapy can reduce overdosing certain patients and improve treatment outcomes.